Home/Filings/4/0001562180-23-004095
4//SEC Filing

Perry Andrew 4

Accession 0001562180-23-004095

CIK 0001560241other

Filed

May 11, 8:00 PM ET

Accepted

May 12, 4:19 PM ET

Size

5.5 KB

Accession

0001562180-23-004095

Insider Transaction Report

Form 4
Period: 2023-05-10
Perry Andrew
Chief Commercial Officer
Transactions
  • Award

    Common Stock

    2023-05-10+35,00056,300 total
Footnotes (3)
  • [F1]Represents a restricted stock unit ("RSU") award that vests 50% on May 10, 2024 and 50% on May 10, 2025, subject to the Reporting Person's continued service through each applicable vesting date.
  • [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
  • [F3]Represents (i) 700 shares of common stock; (ii) 4,500 RSUs from award granted on January 3, 2022; (iii) 16,100 RSUs from award granted on January 3, 2023, and (iv) 35,000 RSUs from award granted on May 10, 2023.

Issuer

G1 Therapeutics, Inc.

CIK 0001560241

Entity typeother

Related Parties

1
  • filerCIK 0001877793

Filing Metadata

Form type
4
Filed
May 11, 8:00 PM ET
Accepted
May 12, 4:19 PM ET
Size
5.5 KB